Regulation of the Cancer Stem Phenotype by Long Non-Coding RNAs

Jose Adan Gutierrez-Cruz 1, Vilma Maldonado 2 and Jorge Melendez-Zajgla 1,*

1 Functional Genomics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City 04710, Mexico; josee92@gmail.com
2 Epigenetics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City 04710, Mexico; vmaldonado@inmegen.gob.mx
* Correspondence: jmelendez@inmegen.gob.mx

Abstract: Cancer stem cells are a cell population within malignant tumors that are characterized by the ability to self-renew, the presence of specific molecules that define their identity, the ability to form malignant tumors in vivo, resistance to drugs, and the ability to invade and migrate to other regions of the body. These characteristics are regulated by various molecules, such as lncRNAs, which are transcripts that generally do not code for proteins but regulate multiple biological processes through various mechanisms of action. LncRNAs, such as HOTAIR, H19, LncTCF7, LUCAT1, MALAT1, LINC00511, and FMR1-AS1, have been described as key regulators of stemness in cancer, allowing cancer cells to acquire this phenotype. It has been proposed that cancer stem cells are clinically responsible for the high recurrence rates after treatment and the high frequency of metastasis in malignant tumors, so understanding the mechanisms that regulate the stem phenotype could have an impact on the improvement of cancer treatments.

Keywords: stem phenotype; long non-coding RNA; microenvironment; stem cancer cells

1. Introduction

Cancer is one of the leading causes of death worldwide. According to the World Health Organization, in 2020, there were an estimated 18.1 million new cases and 9.9 million deaths worldwide. The most frequently diagnosed malignant tumors are breast, lung, colorectal, prostate, and stomach cancers, while the leading causes of death are lung, breast, colorectal, liver, and stomach cancers [1]. The main causes of death from these diseases are recurrence after treatment [2] and the development of metastases [3], which are caused by the appearance of aggressive cell populations such as cancer stem cells [4,5]. These cells are a subpopulation of malignant tumor cells that possess the ability to self-renew [6], differentiate into non-stem cancer cells that are part of the heterogeneity of the malignant tumor [7], and evade many of the drugs directed against proliferating cancer cells [8]. Stem cells or tumor-initiating cells (TICs) express receptors, transcription factors, and microRNAs that define their identity [9,10] and enhance their ability to invade and migrate to other regions of the body to form new malignant tumors [11]. Among the molecules involved in the regulation of stemness or stem phenotype are long non-coding RNAs (lncRNAs), which are transcripts larger than 200 nucleotides that, for the most part, do not have an open reading frame [12] but regulate multiple biological processes, such as cell proliferation [13], cell death [14], differentiation [15], and cell homeostasis [16]. These effects are mediated by several mechanisms, including acting as scaffolds for proteins complexes, decoys for miRNAs, sponges for microRNAs, and guides for transcription factors. In this review, we describe the relationship between lncRNAs and the acquisition of the stem phenotype by cancer cells, as well as the biological implications of this relationship.
2. Cancer Stem Cells

Malignant tumors are composed of heterogeneous cell populations [17,18] with different genetic [19], epigenetic [20], and phenotypic [21] alterations. One of the cell populations that has attracted the attention of scientists in recent years is cancer stem cells. These cells are a cell population within malignant tumors that possess several characteristics (Figure 1) that, at the clinical level, are responsible for recurrence after surgery or treatment with antineoplastic drugs and radiotherapy [22,23], in addition to the high rate of metastasis generated in many cancers [24], which are the main causes of death in most malignant tumors [3]. Cancer stem cells (CSC) represent an interesting target for therapy, as they are responsible for these clinical features, and their elimination could result in increased survival rates and even eradication of the disease. Since their discovery in the 1990s by John Dick’s work group in acute myeloid leukemia [4], there have been numerous studies in which populations of these cancer cells have been reported. To date, cancer stem cells have been identified in breast cancer [5,25,26], colorectal cancer [27–31], stomach cancer [32], lung cancer [33], and prostate cancer [34], among other malignant tumors.

![Figure 1. Characteristics that define the stem phenotype in cancer. Cancer cells can transition between a state of stemness and non-stemness generated by multiple genetic and epigenetic alterations, the tumor microenvironment, and the activation of signaling programs such as EMT. These processes allow cancer cells to acquire the ability to metastasize, express membrane proteins or specific intracellular molecules, self-renew, have a high tumorigenic capacity in vivo, and generate resistance to many conventional cancer treatments.](image-url)

Cancer stem cells can originate from normal tissue stem or progenitor cells that have accumulated genetic and epigenetic alterations, causing their transformation to cancer cells [35]; however, it has also been proposed that cancer cells can acquire a stem phenotype.
in response to epigenetic modifications and stimuli generated by the tumor microenvironment [36].

**Characteristics of the Stem Phenotype**

The stem phenotype is defined by a series of characteristics that cancer cells acquire during the development of the malignant tumor [37]. These characteristics are similar to those possessed by normal stem cells that are found at the base of every tissue in our body [38]; hence, one of the proposals to explain the origin of cancer stem cells is that of the conversion of a normal stem cell that has acquired genetic and epigenetic alterations that lead to its conversion to a cancer stem cell [39]. The main characteristics that define the cancer stem phenotype are described below:

- **Self-renewal.** This is the ability of cancer stem cells to divide asymmetrically [40], causing one of the daughter cells resulting from cell division to maintain its stem characteristics [41] and the other resulting daughter cell to begin the process of a restricted differentiation program without the stem cell capabilities [42]. Cancer stem cells maintain their population at a constant level through this feature, allowing the malignant tumor to reform when, for example, non-stem cancer cells are pharmacologically eliminated [43].

- **Tumorigenic ability.** Cancer cells with a stem phenotype possess the ability to initiate and maintain a malignant tumor when transplanted into immunodeficient mice [4,5]. A small number of them is sufficient to recapitulate the malignant tumor from which they originate when transferred in this type of mouse [44,45], in contrast to non-stem cancer cells, which present a reduced tumor-forming ability [46].

- **Drug resistance.** Cancer stem cells are able to evade many conventional chemotherapeutic drugs [47,48]. These cells can remain quiescent for long periods of time, so drugs directed toward proliferating cells do not affect them, as they are not dividing [49]. Another mechanism involved in their drug resistance is the expression of ATP-dependent membrane transporters of the ABC family [50] or isoforms of aldehyde dehydrogenase enzymes, which allow the expulsion of drugs more efficiently than in cancer cells that do not express these proteins [51].

- **Marker expression:** The expression of specific molecules is one of the features that has allowed the identification, isolation and enrichment of cancer stem cells. The markers range from surface proteins, such as CD44 [32], CD133 [33], CD24 [5], EpCAM (epithelial cell adhesion molecule) [52], etc., to molecules with enzymatic activity, such as isoforms 1A1 and 1A3 of the enzyme aldehyde dehydrogenase (ALDH) [25,26]. In general, cancer stem cells usually express some of the transcription factors associated with pluripotency, such as SOX2, NANOG and OCT4) [53,54]. Table 1 lists the main markers that define the stem phenotype in the most common solid tumors.

| Markers | Tumor | References |
|---------|-------|------------|
| CD44⁺ CD24⁻/low, CD44⁺ CD24⁻, CD44⁺ CD24⁻ CD24 EpCAM⁺, ALDH enzyme activity (isoforms 1A1, 1A3) | Breast cancer | [5,25,26] |
| CD133, CD166, CD44, LGR5, ALDH1A1 enzyme activity | Colorectal cancer | [27–33] |
| CD44⁺ | Stomach cancer | [32] |
| CD133⁺ | Lung cancer | [33] |
| CD133⁺, CD44⁺ | Prostate cancer | [33,34] |
| CD44⁺ CD24⁺ EpCAM⁺, CD133⁺ CD44⁺, ALDH enzyme activity. | Pancreatic cancer | [52,55,56] |
| CD133⁺ | Brain cancer | [57] |

- **Metastasis.** It has been proposed that cancer stem cells are able to migrate to other regions of the body and form new malignant tumors (metastasis) by activating the
EMT (epithelial-mesenchymal transition) program that allows the conversion of an
epithelial cell to a mesenchymal cell [11,58]. To perform this process, cancer stem
cells present activated signaling cascades that regulate transcription factors such as
SNAIL (snail family transcriptional repressor 1), SLUG (snail family transcriptional
repressor 2), ZEB1 (zinc finger E-Box binding homeobox 1), and ZEB2 (zinc finger E-Box
binding homeobox 2) [59–62].

Cancer cells possess highly dynamic phenotypic plasticity. This plasticity allows these
cells to acquire stem characteristics in response to microenvironmental stimuli [63] such as
hypoxic conditions [64], absence of nutrients (metabolic reprogramming) [65], cytokines
secreted by the cancer cells themselves or cells of the immune system [66], and selection
pressures such as the use of drugs [67]. The acquisition of the stem phenotype makes
these cells difficult to eliminate, as it confers capabilities that favor their survival and thus
progression to more aggressive stages of cancer in patients [68]. At the molecular level, the
stem phenotype is regulated by multiple molecules that interact with each other to maintain
this state in cancer cells. Among the signaling systems associated with the maintenance
of stemness in cancer are the WNT/β-catenin [69], Notch [70], Sonic Hedgehog [71], and
Hippo YAP/TAZ [72] signaling pathways, in addition to the activity of transcripts such as
miRNAs [73] and lncRNAs [74].

3. LncRNAs Regulate Gene Expression

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that
generally do not code for functional proteins [75]. Most of these transcripts are synthesized
by RNA polymerase II [76] and, like many of the RNAs described to date, have a long
adenine sequence at the 3’ end and a cap at the 5’ end (7 methyl guanosine) [77]. lncRNAs
regulate multiple biological processes, such as proliferation [78], differentiation [79], cell
death, etc. [80]. To date, more than 28,000 lncRNAs have been described in humans
(according to the FANTOM5 project); however, we only know the function of some of them [81] (Figure 2).

LncRNAs can be transcribed from different regions of the genome and, according
to their location in the genome, they are classified into sense lncRNAs, when transcribed
from the sense strand of a coding gene (overlapping with exons or introns) [82]; antisense
lncRNAs, located on the antisense strand of a coding gene [83]; intronic lncRNAs, produced
from intronic regions of coding genes [84]; bidirectional lncRNAs, formed on the opposite
strand and direction of a coding gene [85]; enhancer lncRNAs, which are derived from
genome sequences that act as enhancers [86]; and intergenic lncRNAs, located in regions
located between coding genes [87]. LncRNAs regulate multiple processes for cell home-
ostasis, so their mechanisms for carrying out this work are also varied. These RNAs can be
 grouped according to their molecular mechanism of action, into the categories listed below:

• Scaffolds: lncRNAs can form secondary structures that allow them to bind to proteins
to form complexes that carry out particular functions in the cell [88]. An example of a transcript with this mechanism of action is lncRNA-NEAT1 (nuclear paraspeckle
assembly transcript 1), which interacts with the protein subunit EZH2 (enhancer of
zeste 2 polycomb repressive complex 2 subunit) of the chromatin remodeling complex
PCR2 (polycomb repressive complex 2), which functions as a transcriptional repressor of
different genes [89] (Figure 2).

• Sponges: lncRNAs with this mechanism of action present target miRNAs sequences, so
they can prevent these miRNAs from carrying out their function by directly interacting
with them. The miRNAs are complementary to the lncRNA sequence [90]. Among
the transcripts with this mechanism of action is lncRNA-SNHG7 (small nucleolar RNA
hostgene 7), which is found abundantly in the cell and hijacks miR-216b, blocking its
activity by competing as a binding site against its target messenger RNA (mRNA) [91]
(Figure 2).
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that generally do not code for functional proteins [75]. Most of these transcripts are synthesized by RNA polymerase II [76] and, like many of the RNAs described to date, have a long adenine sequence at the 3′ end and a cap at the 5′ end (7 methyl guanosine) [77].

### LncRNAs Regulate Gene Expression

LncRNAs regulate multiple biological processes, such as proliferation [78], differentiation [79], cell death, etc. [80]. To date, more than 28,000 lncRNAs have been described in humans (according to the FANTOM5 project); however, we only know the function of some [81] (Figure 2).

- **Mechanisms of action of lncRNAs.**
  - **Guides:** lncRNAs can interact with chromatin remodeling proteins and transcription factors (TFs) to target specific DNA sequences where gene activation or silencing is required [92]. One of the best studied lncRNAs with this function is HOTAIR (HOX transcript antisense RNA), which mediates the silencing of tumor suppressor genes such as P21 in cancer. In this case, HOTAIR recruits the chromatin remodeling complex PRC2, through its interaction with the EZH2 subunit, to the promoter region of P21, establishing marks that allow the formation of heterochromatin and, therefore, the transcriptional repression of the tumor suppressor gene [93] (Figure 2).
  - **Signals:** Acting as markers in different regions of the genome to signal chromatin remodeling complexes whether transcriptional activation or silencing of genes is required [92]. One of the lncRNAs reported to have this function is XIST (X inactive specific transcript). When this transcript is expressed, it functions as a mark indicating which X chromosome should be silenced, in females. XIST recruits chromatin remodelers, such as PRC2, to the X chromosome that will be repressed to generate heterochromatin [94] (Figure 2).
  - **Decoys:** Preventing proteins or protein complexes such as the transcription initiator complex from carrying out their function, thus impacting gene expression. LncRNAs with decoy activity bind to proteins and DNA, preventing other molecules from interacting with them. In this way, the hijacked protein or DNA sequence cannot interact with its target. The lncRNA TERRA (telomeric-repeat-containing RNA) is an example of lncRNA with decoy activity (Figure 2).

![Figure 2. Mechanisms of action of lncRNAs. (A) Scaffolds. They allow the formation of protein complexes. (B) Guides. They direct gene expression regulatory proteins or transcription factors (TFs) to sites in the genome where activation or inactivation of gene expression is demanded. (C) Sponges. They inhibit the activity of miRNAs by interacting directly with them. (D) Signals. They indicate to chromatin remodeling (CR) proteins the region of the genome where gene activation or silencing is required. (E) Decoy. They prevent the interaction of proteins (P) with their target by interacting directly with them.](image-url)
example of a transcript with this mechanism of action. This lncRNA binds to the active site of the enzyme telomerase, blocking its activity and preventing it from carrying out its function of protecting the telomeric regions of chromosomes [95] (Figure 2).

4. The Role of lncRNAs in the Regulation of the Stem Phenotype in Malignant Tumors

Alteration of lncRNAs expression participates in the development of diseases such as cancer [96]. Their oncogenic or tumor suppressor activity has been associated with all the characteristics or hallmarks that define this group of diseases [97,98]. The stem phenotype is no exception since, in recent years, several research groups around the world have described the role that lncRNAs play in the acquisition and maintenance of this phenotype. Most of the research has been performed in a limited number of tumor types, including breast and gastrointestinal tumors. The most relevant examples of lncRNAs related to stemness in different malignancies are described below.

4.1. Breast Cancer

Globally, breast cancer is the malignant tumor with the highest incidence and the second highest mortality in women [1]. These tumors are highly heterogeneous, and different cell populations that contribute to their development and maintenance have been described [99]. Among the cell populations described in these malignant tumors are cancer stem cells, which were first described in 2003 by Al-Hajj et al. [5]. Their group demonstrated that cancer cells with the CD44+ CD24−/low phenotype had a greater tumorigenic capacity when transplanted into immunodeficient mice (NOD/SCID), compared to those cells that did not have this phenotype. Over time, other markers associated with stemness in these malignancies have been described, such as the expression and activity of the A1A1 and A1A3 isoforms of the ALDH enzyme [25,26]. Among the molecules involved in the regulation of the stem phenotype in breast cancer are lncRNAs (Figure 3). In 2021, Ten et al. reported that Lnc408 was able to regulate the stem phenotype in breast cancer through modulation of the β-catenin protein, which is part of the WNT signaling pathway responsible for regulating stemness in different malignancies [100,101]. This research group demonstrated that, when Lnc408 is expressed, it recruits the transcription factor SP3 to the promoter region of the CBY-1 (protein chibby homolog 1) protein to prevent its expression. CBY-1 acts by inhibiting β-catenin, by interacting directly with it and promoting its degradation. When CBY-1 is absent, β-catenin is not degraded and can perform its activity, activating the WNT signaling pathway. The activation of this signaling pathway promotes the expression of the stem transcription factors SOX2 and NANOG, as well as CD44, which is one of the reported stem markers in breast cancer. This allows cancer cells to acquire a greater ability to form malignant tumors when transplanted into immunodeficient mice. HOTAIR is an additional lncRNA with a similar mechanism of action to Lnc408 [102]. This transcript regulates the expression of miR-304a in cancer stem cells of both MCF-7 and MDA-MB-231 cell lines. HOTAIR increases the expression of the transcription factor SOX2 by epigenetically silencing the expression of this miRNA, which normally negatively regulates the mRNA of this transcription factor. HOTAIR expression in these cell models allows cancer stem cells to self-renew and thus maintain constant populations throughout cell divisions [102]. Microenvironmental conditions play a relevant role in the acquisition of the stem phenotype in cancer, as it has been reported that conditions such as hypoxia allow cancer cells to acquire stemness characteristics [103]. Interestingly, lncRNAs are also involved in this process. In 2021, Zhu et al. reported that hypoxia induces the expression of lncRNA-KB-1980E6.3, which interacts with IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1) protein to form an RNA–protein complex with the C-MYC oncogene mRNA and stabilize it [104]. The formation of this complex promotes the translation of the oncogene mRNA, causing cancer cells to acquire increased malignant tumor-forming capacity in vivo and increased protein levels of pluripotency factors OCT4, SOX2, NANOG and KLF4 (Kruppel-like factor 4). LncRNAs also interact with miRNAs by directly binding
to their nucleotide sequence, sequestering them, and preventing them from carrying out translation inhibition of their target mRNA (Figure 2). LUCAT1 is a type of lncRNA that possesses this mechanism of action. When the expression of this transcript increases, it acts as a sponge for miR-5582-3p, which is a negative regulator of the mRNA transcription factor TCF7L2. The presence of LUCAT1 allows the transcription factor mRNA to be translated into protein which activates the WNT signaling pathway, resulting in cancer cells with stem characteristics [105]. Even though the molecular mechanisms by which lncRNAs regulate stemness have been explored for just a few of them, a relationship between lncRNA expression and the stem phenotype has been clearly established by loss- or gain-of-function assays for a larger number of lncRNAs. For example, this is the case with the lncROPM lncRNA, which is expressed in the CD44+ CD24−/low breast cancer stem cell population. When this lncRNA is inhibited, it decreases the drug resistance, self-renewal, invasiveness, and metastatic capacity of these cells [106]. The list of lncRNAs associated with the regulation of the stemness phenotype in breast cancer continues to grow and the lncRNAs described as regulators of stemness in these malignancies include LINC00617 [107], LncRNA-AGAP2-AS1 [108], LncRNA-HAL [109], LINC00511 [110], LncRNA-H19 [111], LncRNA-HOTTIP (HOXA distal transcript antisense RNA) [112], LncRNA-FEZ1F-AS1 [113], LINC00261 [114], LncRNA-HH [115], LncRNA-SOX21-AS1 [116], LncRNA-NEAT1 [117], LncRNA-ROR (regulator of reprogramming) [118], and MALAT-1 (metastasis associated lung adenocarcinoma transcript 1) [119], among others. Table 2 describes the role of these lncRNAs in the regulation of stemness in breast cancer. Clearly, more research is needed to explore the molecular mechanisms used by lncRNAs to accomplish their regulatory role. The use of new high-throughput techniques such as CRISPR-Cas high-content screening should help to achieve this [120].

4.2. Colorectal Cancer

Colorectal cancer has the second highest incidence and third highest mortality worldwide [1]. These malignant tumors originate in the crypts of the colon, and cancer cell populations with a stem phenotype have also been reported in these malignancies. In 2007, O’Brien et al. reported the presence of CD133+ cells with a high tumor-forming capacity when transplanted into immunodeficient (NOD/SCID) mice [27]. This was the first time that CSCs were detected in colorectal cancer. In recent years, different cancer stem cell populations have been reported in colon cancer, as defined by the markers LGR5+, CD44+, and ALDH positive activity, among others [28,30,31]. LncRNAs have been also described as key regulators of stemness in these malignancies (Figure 4). One of the best described transcripts in this context is H19. This is a lncRNA of approximately 2300 bases located on chromosome 19 that has been associated with different oncogenic processes, such as uncontrolled cell proliferation and metastasis, in many malignant tumors. In colorectal cancer, H19 regulates the stemness of cancer cells with ALDH enzyme activity. When this lncRNA is inhibited, the capacity of tumor formation in immunodeficient mice (NOD/SCID) decreases, as does the resistance to oxaliplatin (a drug frequently used as chemotherapy in this type of cancer) and the proportion of ALDH cells [121]. H19 regulates these processes by acting as a sponge, sequestering miR-141, which normally negatively regulates β-catenin mRNA. Upon overexpression of H19, miR-141 activity is prevented, allowing translation of β-catenin mRNA, and activating the WNT signaling pathway [121]. LncRNAs are able to modulate key pluripotent signaling systems that control stemness in cancer, such as WNT and secondary or restricted stem-associated signaling pathways, such as Sonic Hedgehog. In 2019, Zhou et al. showed that inhibition of lncRNA-cCSC1 decreased the levels of SMO and Gli1 proteins, intermediates of the Hedgehog system [122]. This negative modulation of the signaling pathway decreased in vitro invasion and migration, the protein levels of CD44 and CD133 markers, and the tumor-forming ability of cancer cells in immunodeficient mice (BALB/c), although the exact molecular mechanism by which lncRNAs regulate the Hedgehog pathway remains unknown [122]. Among the processes involved in the maintenance of cancer stem cell populations in malignant tumors is the ability of these cells...
to divide asymmetrically. After a cancer stem cell divides, one of the resulting cells begins
the process of partial differentiation, while the other resulting cell maintains its stem char-
acteristics. The distribution of molecules after division is different in each of these cells. An
example lncRNA regulating this process is Lnc34a, which is expressed in cancer cells with
a stem phenotype but not in cancer cells that have begun the differentiation process [123].
Lnc34a allows cancer stem cells to self-renew by recruiting chromatin remodeling proteins,
such as HDAC1 and DNMT3a (via PHB2), to the promoter region of miR-34a to prevent its
expression. Inhibition of this miRNA by Lnc34a allows cancer stem cells to maintain their
identity through cell divisions. Additional lncRNAs that have been described as regulators
of stemness in colorectal cancer are lncRNA-TUG 1 [124], lncRNA-BCAR4 [125], lncRNA
SLCO4A1-AS1 [126], and lncRNA KLK8 [127].

Figure 3. Mechanism of action of some stemness regulatory lncRNAs in breast cancer. (A) Lnc408
acts as a guide by recruiting chromatin remodelers to the promoter region of CBY-1, preventing its
expression, and allowing the activation of the WNT signaling pathway. (B) LncRNA-KB-1980E6.3
forms an RNA–protein complex that stabilizes the mRNA of the C-MYC oncogene, allowing its
translation, which generates the acquisition of some characteristics that define the stem phenotype.
(C) LUCAT1 is a lncRNA that acts as a sponge of miR-5582-3P, promoting the activation of the
WNT signaling pathway and thus increasing the proportion of CD44⁺CD24⁻ cells. (D) Inhibition
of LncROPM decreases some of the characteristics that define the stem phenotype, although its
mechanism has not yet been elucidated.
Figure 4. Role of lncRNAs in the regulation of the stem phenotype in colorectal cancer. (A) lncRNA H19 functions as a sponge by sequestering miR-141, a negative regulator of β-catenin mRNA, generating the activation of the WNT signaling pathway and increasing the proportion of ALDH cancer stem cells+, among other features. (B) Lnc34a recruits chromatin remodelers to the promoter region of miRNA-34a, blocking its expression. This allows cancer stem cells to self-renew.

4.3. Gastric Cancer

The tumor microenvironment plays an important role in the acquisition of the stem phenotype in cancer [128]. Microenvironment cells (cancerous or otherwise) secrete molecules, such as cytokines, that modify the phenotype of cancer cells [129]. These molecules modulate signaling cascades that culminate in the activation of genes associated with stemness regulation, such as genes encoding for lncRNAs. In gastric cancer, this phenomenon has been widely reported. In 2019, He et al. reported that mesenchymal stem cells in the tumor microenvironment secrete TGF-β1 (transforming growth factor beta 1), which induces the activation of SMAD 2/3 proteins in cancer cells, which promote the expression of lncRNA-MACC1-AS1 [130]. This lncRNA acts as a sponge for miR-145-5p, which negatively regulates mRNAs associated with fatty acid metabolism in the cell. Sequestration of miR-145-5p by lncRNA-MACC1-AS1 induces the expression of stemness markers CD133, OCT4, and SOX2, and increases both oxaliplatin resistance and tumorigenic capacity of cancer cells [130]. Interestingly, lncRNAs can also be secreted by cells from the microenvironment through exosomes and act in as cell-autonomous factors by regulating the stemness phenotype. This is the case for LINC01559, which is secreted by mesenchymal stem cells via exosomes into the tumor microenvironment [131]. Exosomes containing LINC01559 are received by cancer cells, where the lncRNA allows these cells to acquire a greater tumorigenic capacity, the ability to migrate in vitro, and pharmacological resistance. This is achieved through the regulation of the PI3K/AKT signaling pathway. Molecularly, LINC05199 acts as a sponge, sequestering miR-1343-3p and promoting PGK1
(phosphoglycerate kinase 1) mRNA translation into its protein form. The kinase activates the PI3K/AKT signaling pathway, allowing cancer cells to acquire stem-like characteristics. On the other hand, LINC05199 can translocate to the cell nucleus and recruit chromatin remodelers (EZH2) to the promoter region of the phosphatase PTEN (phosphatase and tensin homolog), blocking its expression. This phosphatase is a negative regulator of the PI3K/AKT pathway, so its inhibition leads to the activation of this signaling pathway (Figure 5). Some lncRNAs, such as lncRNA-FEZF1-AS1, regulate the stem phenotype in several tumor types. This is the case for gastric and breast cancer, where the altered expression of this lncRNA results in the regulation of the transcription factors SOX2, OCT4, and NANOG [113,132]. The number of lncRNAs involved in the regulation of cancer stemness points toward a complex signaling redundancy and supports a wider role of these RNAs in the stem phenotype of normal cells.

Figure 5. The tumor microenvironment influences the activation of stemness regulatory lncRNAs in gastric cancer. LncRNAs, such as LINC01559, can be secreted by cells in the microenvironment via exosomes. LINC01559 enters cancer cells and activates the PI3K/AKT signaling pathway. There, it acts as a sponge for miR-1343-3p, allowing the translation of PGK1 kinase mRNA and activating the signaling pathway. In addition, this lncRNA acts as a signal to recruit chromatin remodeling complexes to the PTEN promoter region, preventing its expression. This allows the signaling system to be activated and the cancer cells to acquire capacities associated with the stem phenotype.

4.4. LncRNAs in the Regulation of the Stem Phenotype of Other Types of Cancer

LncRNAs are important modulators of the stem phenotype in the most common malignancies, including leukemias. CSC are key players in leukemia initiation, progression,
and resistance to therapy [133] and lncRNAs also play important roles in maintaining the stem phenotype of these cells. For example, it has been shown that the lncRNA HOTTIP is not only overexpressed in acute myeloid leukemia (AML) patients but is key in maintaining stemness via regulation of the HOXA gene [134]. Additional hematopoietic stem factors are also regulated by lncRNAs in leukemias, such as TET2 and TET3 by MAGI2-As3, HOXA10-AS, and WT1 non-coding RNAs [135,136]. As expected by their targets, these lncRNAs are required for the stem phenotype maintenance, as loss-of-function decreases the number of leukemia stem cells in vivo. More importantly, a therapeutic role for stem-associated lncRNAs can be envisioned. DANCR is a lncRNA that is overexpressed in cytogenetically normal AML patients, with the highest stem subpopulation levels. In vivo experiments showed that DANCR knock-down resulted in decreased stem cell renewal, pointing toward a possible use of this gene for therapy [137].

There are also studies that report the regulation of this phenotype in less common or less investigated malignancies. In 2021, lncRNA-MEG3 was reported to act as a tumor suppressor in oral cancer [138]. Chen and coworkers showed that this lncRNA negatively modulates the WNT signaling pathway by sequestering miR-421 and preventing its activity. Interestingly, lncRNA-MEG3 has also been described as a tumor suppressor in stomach cancer, negatively regulating the JAK/STAT3 signaling pathway by sequestering a different miRNA, miR-708 [139]. In both cancers, the lncRNA reduces the tumor-forming capacity of cancer stem cells when transplanted into immunodeficient mice. Another transcript that regulates stemness in different tumors is LncTCF7. This is a transcript that, in liver cancer, works as a guide to recruit the SWI/WNF chromatin remodeling complex to the promoter region of the TCF7 transcription factor in order to promote its expression. This activates the WNT signaling pathway, allowing cancer stem cells to self-renew [140]. In brain cancer, LncTCF7 negatively regulates miR-200c by sequestering it and inhibiting its activity [141]. This miRNA negatively regulates the mRNA of the stemness marker EpCAM, so its inhibition by LncTCF7 promotes the translation of this mRNA, activating the transcription factors SOX2 and NANOG. At the phenotypic level, this allows cancer stem cells to self-renew and have a greater tumorigenic capacity than non-stem cancer cells. Additional lncRNAs, such as HOTAIR, can act by regulating the stem phenotype in three different malignancies (breast, prostate and pancreatic) through similar mechanisms [102,142,143] (Table 2).

LncRNAs have been shown to be extremely versatile molecules in terms of mechanisms of regulation of the stem phenotype, so the alteration of their activity and their effect on this phenotype are still being described. Additional lncRNAs associated with the stem phenotype in cancer include GAS5 (growth arrest specific 5) [144], LncRNA-RP11-567G11.1, LncRNA-UC.345, and LncRNA STXB5-AS1 (STXB5 antisense RNA 1) in pancreatic cancer; LncRNA HAND2-AS1 (heart and neural crest derivatives expressed transcript 2 antisense RNA 1) [145] in liver cancer; LncRNA-UCA1 (urothelial carcinoma associated 1) in cervical cancer; and FMR1-AS1 (FMR1 antisense RNA 1) [146] in esophageal cancer. Table 2 describes the relationship between these lncRNAs and the stem phenotype.

**Table 2.** LncRNAs that regulate the stem phenotype in the most common cancers.

| LncRNA         | Genes/Signaling Pathway Involved                  | Tumor       | References       |
|---------------|-------------------------------------------------|-------------|-----------------|
| LncRNA-AGAP2-AS1 | SOX2, OCT4                                    | Breast      | [108]           |
| Lnc408        | CBY-1/WNT signaling pathway                     | Breast      | [147]           |
| LncRNA-HOTTIP | miR-148a-3p/Wnt pathway                         | Breast      | [112]           |
| LncRNA-ROPIM  | Not addressed                                   | Breast      | [106]           |
| LINC00617     | CD44+ CD24−                                    | Breast      | [107]           |
| LncRNA-HAL    | CD44+ CD24− via NANOG and ALDH1A3.             | Breast      | [109]           |
| LncRNA-KB-1980E6.3 | IGF2BP1-c-Myc                              | Breast      | [104]           |
Table 2. Cont.

| LncRNA               | Genes/Signaling Pathway Involved                                                                 | Tumor          | References |
|---------------------|-------------------------------------------------------------------------------------------------|----------------|------------|
| HOTAIR             | miR-34a-SOX2                                                                                | Breast         | [102]      |
|                    | miRNA-590-sp-JAK/STAT3 signaling pathway                                                       | Prostate       | [142]      |
|                    | miR-34a-JAK2/STAT3                                                                           | Pancreas       | [143]      |
| LncRNA-FEZF1-AS1    | miR-30a-NANOG                                                                                 | Breast         | [113]      |
|                    | miR-363-3p-SOX2, NANOOG and OCT4                                                              | Stomach        | [132]      |
| LINC00261          | miRNA-550a-3p                                                                                 | Breast         | [114]      |
| LUCAT1             | miR-5582-3p-TCF7L2/WNT signaling pathway                                                       | Breast         | [105]      |
| LncRNA-Hh           |                                                                                               | Breast         | [115]      |
| LncRNA-SOX21-AS1   | Hippo YAP/TAZ signaling pathway                                                               | Breast         | [116]      |
| LncRNA-NEAT1       | SOX2                                                                                          | Breast         | [117]      |
| LncRNA-ROR         | EMT program (ZEB1, ZEB2, TWIST, SLUG and SNAIL)                                               | Breast         | [118]      |
| LncRNA-H19         | let-7                                                                                         | Breast         | [111]      |
| LINC00511          | miR-141-β-catenin                                                                             | Colorectal     | [121]      |
| MALAT-1            | SOX2                                                                                          | Breast         | [119]      |
| LncRNA-BTUG       |                                                                                               | Colorectal     | [124]      |
| LncRNA-CCAR4       | miR-665                                                                                       | Colorectal     | [125]      |
| LncRNA SLCO4A1-AS1 | miR-150-3p-SLCO4A1                                                                           | Colorectal     | [126]      |
| LncRNA cCSC1       | SMO/GLI1 (Hedgehog signaling pathway)                                                          | Colorectal     | [122]      |
| LncRNA KLK8        | SOX2, OCT4 and NANOG                                                                          | Colorectal     | [127]      |
| LncRNA-34a         | miR-34a-DNMT3a/HDAC1                                                                          | Colorectal     | [123]      |
| LncRNA-RP11-567G11.1| JAGGED1, HES1 and HESS (Notch signaling pathway)                                              | Pancreas       | [148]      |
| LncRNA-TUG1        |                                                                                               | Pancreas       | [149]      |
| LncRNA-BCAR4       |                                                                                               | Pancreas       | [124]      |
| LncRNA SLCO4A1-AS1 | miR-150-3p-SLCO4A1                                                                           | Colorectal     | [126]      |
| LncRNA cCSC1       | SMO/GLI1 (Hedgehog signaling pathway)                                                          | Colorectal     | [122]      |
| LncRNA-34a         | miR-34a-DNMT3a/HDAC1                                                                          | Colorectal     | [123]      |
| LncRNA-34a         | miR-34a-DNMT3a/HDAC1                                                                          | Colorectal     | [123]      |
| LncRNA-RP11-567G11.1| JAGGED1, HES1 and HESS (Notch signaling pathway)                                              | Pancreas       | [149]      |
| LncRNA-UCAR4       |                                                                                               | Pancreas       | [150]      |
| LncRNA-uc.345      | SOX2, OCT4 and NANOG                                                                          | Pancreas       | [151]      |
| LNC01559           | miR-1343-3p-P10K/PI3K signaling pathway                                                        | Stomach        | [131]      |
| LncRNA-MACC1-AS1   | TGF-β signaling pathway-miR-145-5P                                                               | Stomach        | [130]      |
| LncRNA-MEG3        | miR-708-SOCS3-JAK/STAT3 pathway                                                                | Stomach        | [139]      |
| FMRI-214           | NF-κB/c-Myc signaling pathway                                                                  | Oral           | [138]      |
| LncRNA-34a         |                                                                                               | Oral           | [138]      |
| LncRNA HAND2-AS1   | INO80 chromatin remodeling complex-BMPR1A-BMP signaling pathway                               | Liver          | [145]      |
| LncRNA TCF7        | SWI/SNF chromatin remodeling complex-TCF7-WNT signaling pathway                              | Liver          | [140]      |
|                    | miR-200c-EpCAM                                                                                | Brain (Glioma) | [141]      |
| LncRNA-UCAR4       | miR-122-5p-SOX2                                                                               | Cervical       | [152]      |

5. Conclusions

Cancer cells are capable of transitioning between a state of stemness and non-stemness in response to different stimuli from the microenvironment, genetic or epigenetic alterations, and the activation of cellular development programs such as EMT. These alterations confer
to cancer stem cells the ability to self-renew, present a high tumorigenic capacity, express key molecules to maintain stem identity, increase drug resistance, and enhance their ability to migrate to form new tumors. Recently, it has been shown that lncRNAs are able to participate in the regulation of the stem phenotype. Transcripts such as LINC00511, HOTAIR, H19, and Lnc304a, among others, have been shown to be key players in the modulation of these capacities. These studies indicate that lncRNAs could represent an interesting target for therapy. The understanding of the mechanisms involved in the regulation of stemness and its repercussions at the biological and clinical level in cancer could lead to the development of new treatments and, probably, with this, to the reduction of mortality caused by malignant tumors.

Author Contributions: Conceptualization J.A.G.-C.; writing-original draft preparation, J.A.G.-C., J.M.-Z. and V.M.; writing, review and editing, J.A.G.-C., J.M.-Z. and V.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by CONACyT grant number A1-S-8462. Adan Gutierrez was supported by a scholarship from CONACyT.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Marzagalli, M.; Fontana, F.; Raimondi, M.; Limonta, P. Cancer Stem Cells-Key Players in Tumor Relapse. Cancers 2021, 13, 376. [CrossRef] [PubMed]
3. Dillekäs, H.; Rogers, M.S.; Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019, 8, 5574–5576. [CrossRef] [PubMed]
4. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645–648. [CrossRef] [PubMed]
5. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983–3988. [CrossRef] [PubMed]
6. Shenghui, H.; Nakada, D.; Morrison, S.J. Mechanisms of Stem Cell Self-Renewal. Annu. Rev. Cell Dev. Biol. 2009, 25, 377–406. [CrossRef] [PubMed]
7. Kumon, K.; Afify, S.M.; Hassan, G.; Ueno, S.; Monzur, S.; Nawara, H.M.; Quora, H.A.A.; Sheta, M.; Xu, Y.; Fu, X.; et al. Differentiation of cancer stem cells into erythroblasts in the presence of CoCl2. Sci. Rep. 2021, 11, 23977. [CrossRef] [PubMed]
8. Li, Y.; Wang, Z.; Ajan, J.A.; Song, S. Drug resistance and Cancer stem cells. Cell Commun. Signal. 2021, 19, 19. [CrossRef]
9. Leng, Z.; Xia, Q.; Chen, J.; Li, Y.; Xu, J.; Zhao, E.; Zheng, H.; Ai, W.; Dong, J. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer. Cell. Physiol. Biochem. 2018, 46, 860–872. [CrossRef]
10. Zhang, H.; Brown, R.L.; Wei, Y.; Zhao, P.; Liu, S.; Liu, X.; Deng, Y.; Hu, X.; Zhang, J.; Gao, X.D.; et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019, 33, 166–179. [CrossRef]
11. Liao, W.T.; Ye, Y.P.; Deng, Y.J.; Bia, X.W.; Ding, Y.Q. Metastatic cancer stem cells: From the concept to therapeutics. Annu. J. Stem Cells 2014, 3, 46–62. [PubMed]
12. Gao, N.; Li, Y.; Li, J.; Gao, Z.; Yang, Z.; Li, Y.; Liu, H.; Fan, T. Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers. Front. Oncol. 2020, 10, 598817. [CrossRef] [PubMed]
13. Xiao, X.; Li, L.; Cui, J.C.; Wang, Y. LncRNA FALEC promotes proliferation, migration, and invasion of PTC cells through regulating Wnt/beta-catenin signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 4361–4367.
14. Chen, L.; Yang, W.; Guo, Y.; Chen, W.; Zheng, P.; Zeng, J.; Tong, W. Exosomal lncRNA GASS regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis. PLoS ONE 2017, 12, e0185406. [CrossRef] [PubMed]
15. Zhang, Z.-K.; Li, J.; Guan, D.; Liang, C.; Zhuo, Z.; Liu, J.; Lu, A.; Zhang, G.; Zhang, B.-T. A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. J. Cachexia Sarcopenia Muscle 2018, 9, 613–626. [CrossRef]
16. Liu, N.; Kataoka, M.; Wang, Y.; Pu, L.; Dong, X.; Fu, X.; Zhang, F.; Gao, F.; Liang, T.; Pei, J.; et al. LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway. *Basic Res. Cardiol.* 2021, 116, 48. [CrossRef] [PubMed]

17. Cros, J.; Raffeneau, J.; Couvelard, A.; Poté, N. Tumor Heterogeneity in Pancreatic Adenocarcinoma. *Pathobiology* 2017, 85, 64–71. [CrossRef] [PubMed]

18. Zhang, Y.; Zhang, D.; Meng, Q.; Liu, Z.; Xie, H.; Liu, L.; Xu, F.; Chen, X. Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level. *BMC Cancer* 2021, 21, 918. [CrossRef] [PubMed]

19. Ahn, S.; Kim, H.J.; Kang, E.; Kim, E.-K.; Kim, S.H.; Kim, J.H.; Kim, I.A.; Park, S.Y. Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity. *Br. J. Cancer* 2020, 122, 697–704. [CrossRef] [PubMed]

20. Grosselin, K.; Durand, A.; Marsolier, J.; Poitou, A.; Marangoni, E.; Nemat, F.; Dahanani, A.; Lameiras, S.; Reyal, F.; Frenoy, O.; et al. High-throughput single-cell ChiP-seq identifies heterogeneity of chromatin states in breast cancer. *Nat. Genet.* 2019, 51, 1060–1066. [CrossRef]

21. Lei, X.; Lei, Y.; Li, J.-K.; Du, W.-X.; Li, R.-G.; Yang, J.; Li, J.; Li, F.; Tan, H.-B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. *Cancer Lett.* 2020, 470, 126–133. [CrossRef]

22. Khaniki, S.H.; Fakoor, V.; Sales, S.S.; Esmaily, H.; Miri, H.H. Risk of relapse and death from colorectal cancer and its related factors using non-Markovian Multi-State model. *Gastroenterol. Hepatol. Bed Bench* 2020, 13, 200–208.

23. Walcher, L.; Kistenmacher, A.-K.; Suo, H.; Kitte, R.; Dluczek, S.; Strauß, A.; Blaudszun, A.-R.; Yevsa, T.; Fricke, S.; Kossatz-Boehlert, U. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. *Front. Immunol.* 2020, 11, 1280. [CrossRef] [PubMed]

24. Seyfried, T.N.; Huentschert, L.C. On the origin of cancer metastasis. *Crit. Rev. Oncog.* 2013, 18, 43–73. [CrossRef] [PubMed]

25. Marcati, P.; Deán, C.A.; Pan, D.; Arasanovia, R.; Gillis, M.; Joshi, M.; Helyer, L.; Pan, L.; Leidal, A.; Gujar, S.; et al. Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells Is Primarily Due To Isoform ALDH1A3 and Its Expression Is Predictive of Metastasis. *Stem Cells* 2011, 29, 32–45. [CrossRef] [PubMed]

26. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 2007, 1, 555–567. [CrossRef]

27. O’Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2006, 445, 106–110. [CrossRef]

28. Todaro, M.; Gaggianesi, M.; Catulano, V.; Benfante, A.; Iovino, F.; Biffoni, M.; Apuzzo, T.; Sperduti, I.; Volpe, S.; Corocullo, G.; et al. CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. *Cell Stem Cell* 2014, 14, 342–356. [CrossRef] [PubMed]

29. Levin, T.G.; Powell, A.E.; Davies, P.S.; Silk, A.D.; Dismuke, A.D.; Andersson, E.C.; Swain, J.R.; Wong, M.H. Characterization of the intestinal stem cell cancer marker CD166 in the human and mouse gastrointestinal tract. *Gastroenterology* 2010, 139, 2072–2082.e2075. [CrossRef] [PubMed]

30. Huang, E.H.; Hynes, M.J.; Zhang, T.; Ginestier, C.; Dontu, G.; Appelman, H.; Fields, J.Z.; Wicha, M.S.; Boman, B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res.* 2009, 69, 3382–3389. [CrossRef]

31. Barker, N.; van Es, J.H.; Kuipers, J.; Kuilala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007, 449, 1003–1007. [CrossRef] [PubMed]

32. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S.S.W.; Shibata, W.; Vigneshwaran, R.; Gordon, S.A.K.; Shimada, Y.; Wang, T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. *Stem Cells* 2009, 27, 1006–1020. [CrossRef]

33. Leung, E.L.-H.; Fiscus, R.R.; Tung, J.W.; Tin, V.P.-C.; Cheng, L.C.; Sihoo, A.D.-L.; Fink, L.M.; Ma, Y.; Wong, M.P. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. *PLoS ONE* 2010, 5, e14062. [CrossRef]

34. Patrawala, L.; Calhou, T.; Schneider-Brossard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J.G.; Chandra, D.; Zhou, J.; Claypool, K.; et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. *Oncoogene* 2006, 25, 1695–1708. [CrossRef] [PubMed]

35. Kreso, A.; Dick, J.E. Evolution of the Cancer Stem Cell Model. *Cell Stem Cell* 2014, 14, 275–291. [CrossRef]

36. Cabrera, M.C.; Hollingsworth, R.E.; Hurt, E.M. Cancer stem cell plasticity and tumor hierarchy. *World J. Stem Cells* 2015, 7, 27–36. [CrossRef]

37. Butti, R.; Gunasekaran, V.P.; Kumar, T.V.S.; Banerjee, P.; Kundu, G.C. Breast cancer stem cells: Biology and therapeutic implications. *Int. J. Biochem. Cell Biol.* 2019, 107, 38–52. [CrossRef]

38. Papaccio, F.; Paino, F.; Regad, T.; Papaccio, G.; Desiderio, V.; Tirino, V. Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. *Stem Cells Transl. Med.* 2017, 6, 2115–2125. [CrossRef]

39. Prager, B.C.; Xie, Q.; Bao, S.; Rich, J.N. Cancer Stem Cells: The Architects of the Tumor Ecosystem. *Cell Stem Cell* 2019, 24, 41–53. [CrossRef]

40. Koguchi, M.; Nakahara, Y.; Ito, H.; Wakamiya, T.; Yoshioka, F.; Ogata, A.; Inoue, K.; Masuoka, J.; Izumi, H.; Abe, T. BMP4 induces asymmetric cell division in human glioma stem-like cells. *Oncol. Lett.* 2020, 19, 1247–1254. [CrossRef]
41. Winquist, R.J.; Hall, A.B.; Eustace, B.K.; Furey, B.F. Evaluating the immortal strand hypothesis in cancer stem cells: Symmetric/self-renewal as the relevant surrogate marker of tumorigenicity. Biochem. Pharmacol. 2014, 91, 129–134. [CrossRef]

42. Lee, S.I.; Roney, M.S.I.; Park, J.H.; Baek, J.Y.; Park, J.; Kim, S.K.; Park, S.K. Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells. Prostate 2019, 79, 720–731. [CrossRef] [PubMed]

43. Hu, J.; Mirshahidi, S.; Simental, A.; Lee, S.C.; De Andrade Filho, P.A.; Peterson, N.R.; Duerksen-Hughes, P.; Yuan, X. Cancer stem cell self-renewal as a therapeutic target in human oral cancer. Oncogene 2019, 38, 5440–5456. [CrossRef] [PubMed]

44. Metzger, E.; Stepputtis, S.S.; Strietz, J.; Preca, B.-T.; Urban, S.; Willmann, D.; Allen, A.; Zenk, F.; Iovino, N.; Bronsert, P.; et al. KDM4 Inhibition Targets Breast Cancer Stem-like Cells. Cancer Res. 2017, 77, 5900–5912. [CrossRef]

45. Vazquez-Santillan, K.; Melendez-Zajgla, J.; Jimenez-Hernandez, L.E.; Gaytan-Cervantes, J.; Munoz-Galindo, L.; Pina-Sanchez, P.; Martinez-Ruiz, G.; Torres, J.; Garcia-Lopez, P.; Gonzalez-Torres, C.; et al. NF-kappaB-inducing kinase regulates stem cell phenotype in breast cancer. Sci. Rep. 2016, 6, 37340. [CrossRef] [PubMed]

46. Qin, T.; Li, B.; Feng, X.; Fan, S.; Liu, L.; Liu, D.; Mao, J.; Lu, Y.; Yang, J.; Yu, X.; et al. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. J. Exp. Clin. Cancer Res. 2018, 37, 287. [CrossRef] [PubMed]

47. Zhang, S.; Zhang, H.; Ghia, E.M.; Huang, J.; Wu, L.; Zhang, J.; Lam, S.; Lei, Y.; He, J.; Cui, B.; et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc. Natl. Acad. Sci. USA 2019, 116, 1370–1377. [CrossRef] [PubMed]

48. Lee, S.H.; Reed-Newman, T.; Anant, S.; Ramasamy, T.S. Regulatory Role of Quiescence in the Biological Function of Cancer Stem Cells. Stem Cell Rev. Rep. 2020, 16, 1185–1207. [CrossRef] [PubMed]

49. Smith, A.G.; Macleod, K.F. Autophagy, cancer stem cells and drug resistance. J. Pathol. 2019, 247, 708–718. [CrossRef]

50. Begic, H.; Lanka, T.; Falasca, M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int. J. Mol. Sci. 2017, 18, 2362. [CrossRef]

51. Januchowski, R.; Wojtowicz, K.; Zabel, M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. 2013, 67, 669–680. [CrossRef] [PubMed]

52. Nomura, A.; Banerjee, S.; Chugh, R.; Dudeja, V.; Yamamoto, M.; Vickers, S.M.; Saluja, A.K. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget 2015, 6, 8313–8322. [CrossRef] [PubMed]

53. Lu, H.; Xie, Y.; Tran, L.; Lan, J.; Yang, Y.; Murugan, N.L.; Wang, R.; Wang, Y.J.; Semenza, G.L. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J. Clin. Investig. 2020, 130, 4607–4623. [CrossRef] [PubMed]

54. Kaufhold, S.; Garban, H.; Bonavida, B. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. J. Exp. Clin. Cancer Res. 2016, 35, 84. [CrossRef]

55. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of Pancreatic Cancer Stem Cells. Cancer Res. 2007, 67, 1030–1037. [CrossRef]

56. Kim, M.P.; Fleming, J.B.; Wang, H.; Abbruzzese, J.L.; Choi, W.; Kopetz, S.; McConkey, D.J.; Evans, D.B.; Gallick, G.E. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011, 6, e20636. [CrossRef]

57. Brescia, P.; Ortensi, B.; Fornasari, L.; Levi, D.; Brogi, G.; Pelicci, G. CD133 Is Essential for Glioblastoma Stem Cell Maintenance. Stem Cells 2013, 31, 857–869. [CrossRef] [PubMed]

58. Tanabe, S.; Quader, S.; Cabral, H.; Ono, R. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. Front. Pharmacol. 2020, 11, 904. [CrossRef] [PubMed]

59. Zhou, W.; Lv, R.; Qi, W.; Wu, D.; Xu, Y.; Liu, W.; Mou, Y.; Wang, L. Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PLoS ONE 2014, 9, e87409. [CrossRef] [PubMed]

60. Zhou, L.; Wang, D.; Sheng, D.; Xu, J.; Chen, W.; Qin, Y.; Du, R.; Yang, X.; He, H.; Xie, N.; et al. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics 2020, 10, 2405–2421. [CrossRef]

61. Pérez, G.; López-Moncada, F.; Indo, S.; Torres, M.; Castellón, E.; Contreras, H. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells. Oncol. Rep. 2021, 45, 58. [CrossRef]

62. Li, N.; Babaei-Jadidi, R.; Lorenzi, F.; Spencer-Dene, B.; Clarke, P.; Domingo, E.; Tulchinsky, E.; Vries, R.G.J.; Kerr, D.; Pan, Y.; et al. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis 2019, 8, 13. [CrossRef] [PubMed]

63. Zheng, X.; Yu, C.; Xu, M. Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy. Front. Oncol. 2021, 11, 678333. [CrossRef] [PubMed]

64. Xiang, L.; Semenza, G.L. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Adv. Cancer Res. 2019, 141, 175–212. [CrossRef]

65. El-Sahli, S.; Wang, L. Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer. Int. J. Mol. Sci. 2020, 21, 9125. [CrossRef]

66. Sultan, M.; Coyle, K.M.; Vidovic, D.; Thomas, M.L.; Gujar, S.; Marcato, P. Hide-and-seek: The interplay between cancer stem cells and the immune system. Carcinogenesis 2016, 38, 107–118. [CrossRef] [PubMed]
70. Dong, P.; Xiong, Y.; Yue, J.; Hanley, S.J.B.; Kobayashi, N.; Todo, Y.; Watari, H. Long Non-coding RNA NEAT1: A Novel Target for Cancer Stem Cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. *Cell Death Dis.* 2017, 8, e2746. [CrossRef] [PubMed]

71. Sharma, A.; De, R.; Javed, S.; Srinivasan, R.; Pal, A.; Bhattacharyya, S. Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition. *J. Cell. Physiol.* 2019, 234, 15726–15741. [CrossRef] [PubMed]

72. Hu, J.K.-H.; Du, W.; Shelton, S.J.; Oldham, M.C.; DiPersio, C.M.; Klein, O.D. An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice. *Cell Stem Cell* 2017, 21, 91–106.e106. [CrossRef]

73. Wu, X.; Zheng, X.; Cheng, J.; Zhang, K.; Ma, C. LncRNA TUG1 regulates proliferation and apoptosis by regulating miR-148b/IGF2 axis in ox-LDL-stimulated VSMC and HUVEC. *Life Sci.* 2020, 243, 117287. [CrossRef] [PubMed]

74. Melendez-Zajgla, J.; Maldonado, V. The Role of IncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. *Int. J. Mol. Sci.* 2021, 22, 6374. [CrossRef] [PubMed]
94. Plath, K.; Mlynarczyk-Evans, S.; Nusinow, D.A.; Panning, B. Xist RNA and the Mechanism of X Chromosome Inactivation. Annual Review of Genetics. 2002, 36, 233–278. [CrossRef] [PubMed]

95. Redon, S.; Reichenbach, P.; Linger, J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic Acids Res. 2010, 38, 5797–5806. [CrossRef]

96. Jiang, M.C.; Ni, J.J.; Cui, W.Y.; Wang, B.Y.; Zhuo, W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am. J. Cancer Res. 2019, 9, 1354–1366. [CrossRef]

97. Ma, S.; Deng, X.; Yang, Y.; Zhang, Q.; Zhou, T.; Liu, Z. The lncRNA LINC00675 regulates cell proliferation, migration, and invasion by affecting Wnt/β-catenin signaling in cervical cancer. Biomed. Pharmacother. 2018, 108, 1686–1693. [CrossRef] [PubMed]

98. Liu, B.; Xiang, W.; Liu, J.; Tang, J.; Wang, J.; Liu, B.; Long, Z.; Wang, L.; Yin, G.; Liu, J. The regulatory role of antisense lncRNAs in cancer. Cancer Cell Int. 2021, 21, 459. [CrossRef]

99. Polyak, K. Heterogeneity in breast cancer. J. Clin. Investig. 2011, 121, 3786–3788. [CrossRef] [PubMed]

100. Teng, Y.; Wang, X.; Wang, Y.; Ma, D. Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 2010, 392, 373–379. [CrossRef] [PubMed]

101. Kim, Y.-M.; Kahn, M. The role of the Wnt signaling pathway in breast cancer stem cells: Prospects for drug development. Res. Rep. Biochem. 2014, 4, 1–12. [PubMed]

102. Deng, J.; Yang, M.; Jiang, R.; An, N.; Wang, X.; Liu, B. Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancers. PLoS ONE 2017, 12, e0170860. [CrossRef]

103. Zhang, Q.; Han, Z.; Zhu, Y.; Chen, J.; Li, W. Role of hypoxia inducible factor-1 in cancer stem cells (Review). Mol. Med. Rep. 2021, 23, 17. [CrossRef] [PubMed]

104. Zheng, A.; Song, X.; Zhang, L.; Zhao, L.; Mao, X.; Wei, M.; Jin, F. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway. J. Exp. Clin. Cancer Res. 2019, 38, 305. [CrossRef]

105. Liu, S.; Sun, Y.; Hou, Y.; Yang, L.; Wang, X.; Qin, Y.; Liu, Y.; Wang, R.; Zhu, P.; Teng, Y.; et al. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell tumorigenesis via targeting miR-30a/Nanog axis. J. Hematol. Oncol. 2021, 14, 178. [CrossRef] [PubMed]

106. Li, H.; Luo, Z.; Li, Y.; Ma, Y.; Lu, J.; Chen, Y.; Dong, H. MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer. Oncogene 2020, 40, 1609–1627. [CrossRef]

107. Zhang, A.; Song, X.; Zhang, L.; Zhao, L.; Mao, X.; Wei, M.; Jin, F. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway. J. Exp. Clin. Cancer Res. 2019, 38, 305. [CrossRef]

108. Li, L.; Meng, D.; Wang, R. Long non-coding RNA SOX21-AS1 enhances the stemness of breast cancer cells via the Hippo pathway. FEBS Open Bio 2021, 11, 251–264. [CrossRef]

109. Shin, V.Y.; Chen, J.; Cheuk, I.W.-Y.; Siu, M.-T.; Ho, C.-W.; Wang, X.; Jin, H.; Kwong, A. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019, 10, 270. [CrossRef]

110. Hou, P.; Zhao, Y.; Li, Z.; Yao, R.; Ma, M.; Gao, Y.; Zhao, L.; Zhang, Y.; Huang, B.; Lu, J. lncRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014, 5, e1287. [CrossRef]

111. Zeng, L.; Cen, Y.; Chen, J. Long non-coding RNA MALAT-1 contributes to maintenance of stem cell-like phenotypes in breast cancer cells. Oncol. Lett. 2018, 15, 2117–2122. [CrossRef]
120. Liu, S.Y.; Yi, G.Q.; Tang, Z.L.; Chen, B. Progress on genome-wide CRISPR/Cas9 screening for functional genes and regulatory elements. *Yi Chuan* **2020**, *42*, 435–443.

121. Ren, J.; Ding, L.; Zhang, D.; Shi, G.; Xu, Q.; Shen, S.; Wang, Y.; Wang, T.; Hou, Y. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. *Theranostics* **2018**, *8*, 3932–3948. [CrossRef]

122. Zhou, H.; Xiong, Y.; Peng, L.; Wang, R.; Zhang, H.; Fu, Z. lncRNA-cSCSl modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. *J. Cell. Biochem.* **2019**, *121*, 2510–2524. [CrossRef]

123. Wang, L.; Bu, P.; Ai, Y.; Srinivasan, T.; Chen, H.J.; Xiang, K.; Lipkin, S.M.; Shen, X. A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division. *eLife* **2016**, *5*, e14620. [CrossRef]

124. Sun, J.; Zhou, H.; Bao, X.; Wu, Y.; Jia, H.; Zhao, H.; Liu, G. lncRNA TUG1 Facilitates Colorectal Cancer Stem Cell Characteristics and Chemoresistance by Enhancing GATA6 Protein Stability. *Stem Cells Int.* **2021**, *2021*, 1075481. [CrossRef]

125. Ouyang, S.; Zhou, X.; Chen, Z.; Wang, M.; Zheng, X.; Xie, M. lncRNA BCA4, targeting to miR-665/STAT3 signaling, maintains cancer stem cell stemness and promotes tumorigenicity in colorectal cancer. *Cancer Cell Int.* **2019**, *19*, 72. [CrossRef] [PubMed]

126. Wu, K.; Xu, T.; Song, X.; Shen, J.; Zheng, S.; Zhang, L.; Tao, G.; Jiang, B. LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1. *Lab. Invest.* **2021**, *101*, 908–920. [CrossRef] [PubMed]

127. Wang, K.; Song, W.; Shen, Y.; Wang, H.; Fan, Z. LncRNA KLKS modulates stem cell characteristics in colon cancer. *Pathol. Res. Pract.* **2021**, *224*, 153437. [CrossRef]

128. Das, M.; Law, S. Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. *Int. J. Biochem. Cell Biol. 2018*, 103, 115–124. [CrossRef]

129. Korkaya, H.; Liu, S.; Wicha, M.S. Regulation of cancer stem cells by cytokine networks: Attacking cancer’s inflammatory roots. *Clin. Cancer Res.* **2011**, *17*, 6125–6129. [CrossRef] [PubMed]

130. He, W.; Liang, B.; Wang, C.; Li, S.; Zhao, Y.; Huang, Q.; Liu, Z.; Yao, Z.; Wu, Q.; Liao, W.; et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. *Oncogene* **2019**, *38*, 4637–4654. [CrossRef] [PubMed]

131. Wang, L.; Bo, X.; Yi, X.; Xiao, X.; Zheng, Q.; Ma, L.; Li, B. Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling. *Cell Death Dis.* **2020**, *11*, 723. [CrossRef]

132. Hui, Y.; Yang, Y.; Li, D.; Wang, J.; Di, M.; Zhang, S.; Wang, S. LncRNA FEZF1-AS1 Modulates Cancer Stem Cell Properties of Human Gastric Cancer through miR-363-3p/HMGA2. *Cell Transpl.* **2020**, *29*, 963689720925059. [CrossRef]

133. Rothe, K.; Porter, V.; Jiang, X. Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. *Int. J. Mol. Sci.* **2019**, *20*, 461. [CrossRef]

134. Luo, H.; Zhu, G.; Xu, J.; Lai, Q.; Yan, B.; Guo, Y.; Fung, T.K.; Zeisig, B.B.; Cui, Y.; Zha, J.; et al. HOTTIP lncRNA Promotes Self-Renewal of Human Liver Cancer Stem Cells through Activation of Wnt Signaling. *Cancer Cell Int.* **2021**, *20*, 4642. [CrossRef]

135. Al-Kershi, S.; Bhayadia, R.; Ng, M.; Verboon, L.; Emmrich, S.; Gack, L.; Schwarzer, A.; Strowig, T.; Heckl, D.; Klusmann, J.H. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. *Blood Adv.* **2019**, *3*, 4252–4263. [CrossRef]

136. Chen, L.; Fan, X.; Zhu, J.; Chen, X.; Liu, Y.; Zhou, H. lncRNA MAGI2-AS3 inhibits the self-renewal of leukemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia. *RNA Biol.* **2020**, *17*, 784–793. [CrossRef]

137. Bill, M.; Papaioannou, D.; Karunaisri, M.; Kohlschmidt, J.; Pepe, F.; Walker, C.J.; Walker, A.E.; Brannan, Z.; Pathmanathan, A.; Zhang, X.; et al. Expression and functional relevance of long non-coding RNAs in acute myeloid leukaemia stem cells. *Leukemia* **2019**, *33*, 2169–2182. [CrossRef] [PubMed]

138. Chen, P.-Y.; Hsieh, P.-L.; Peng, C.-Y.; Liao, Y.-W.; Yu, C.-H.; Yu, C.-C. LncRNA MEG3 inhibits self-renewal and invasion abilities of oral cancer stem cells by sponging miR-421. *J. Formos. Med. Assoc.* **2021**, *110*, 1137–1142. [CrossRef] [PubMed]

139. Zhang, S.; Ji, W.-W.; Wei, W.; Zhan, L.-X.; Huang, X. Long noncoding RNA Meg3 sponges miR-708 to inhibit intestinal tumorigenesis via SOCS5-repressed cancer stem cell growth. *Cell Death Dis.* **2021**, *13*, 25. [CrossRef] [PubMed]

140. Wang, Y.; He, L.; Du, Y.; Zhu, P.; Huang, G.; Luo, J.; Yan, X.; Ye, B.; Li, C.; Xia, P.; et al. The Long Noncoding RNA IncTFC7 Promotes Self-Renewal of Human Liver Cancer Stem Cells through Activation of Wnt Signaling. *Cell Stem Cell* **2015**, *16*, 413–425. [CrossRef]

141. Zhao, J.; Zhang, L.; Zheng, L.; Hong, Y.; Zhao, L. LncRNA TFC7 promotes the growth and self-renewal of glioma cells via suppressing the miR-200c-EpCAM axis. *Biomed. Pharmacother.* **2018**, *97*, 203–208. [CrossRef]

142. Wang, N.; Jiang, Y.; Lv, S.; Wen, H.; Wu, D.; Wei, Q.; Dang, Q. HOTAIR expands the population of prostatic cancer stem-like cells and causes Docetaxel resistance via activating STAT3 signaling. *Aging* **2020**, *12*, 12771–12782. [CrossRef] [PubMed]

143. Deng, S.; Wang, J.; Zhang, L.; Li, J.; Jin, Y. LncRNA HOTAIR Promotes Cancer Stem-Like Cells Properties by Sponging miR-34a to Activate the JAK2/STAT3 Pathway in Pancreatic Ductal Adenocarcinoma. *Onco Targets Ther.* **2021**, *14*, 1883–1893. [CrossRef]

144. Liu, B.; Wu, S.; Ma, J.; Yan, S.; Xiao, Z.; Wan, L.; Zhang, F.; Shang, M.; Mao, A. lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOC53 in Pancreatic Cancer. *Mol. Ther. Nucleic Acids* **2018**, *3*, 472–482. [CrossRef]

145. Wang, Y.; Zhu, P.; Luo, J.; Wang, J.; Liu, Z.; Wu, W.; Du, Y.; Ye, B.; Wang, D.; He, L.; et al. LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling. *EMBO J.* **2019**, *38*, e101110. [CrossRef] [PubMed]
146. Li, W.; Zhang, L.; Guo, B.; Deng, J.; Wu, S.; Li, F.; Wang, Y.; Lu, J.; Zhou, Y. Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma. *Mol. Cancer* 2019, 18, 22. [CrossRef] [PubMed]

147. Wen, S.; Qin, Y.; Wang, R.; Yang, L.; Zeng, H.; Zhu, P.; Li, Q.; Qiu, Y.; Chen, S.; Liu, Y.; et al. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels. *Cell Death Dis.* 2021, 12, 437. [CrossRef] [PubMed]

148. Jiao, F.; Hu, H.; Han, T.; Yuan, C.; Wang, L.; Jin, Z.; Guo, Z.; Wang, L. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. *Int. J. Mol. Sci.* 2015, 16, 6677–6693. [CrossRef]

149. Huang, R.; Nie, W.; Yao, K.; Chou, J. Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression. *Biomed. Pharmacother.* 2019, 112, 108685. [CrossRef]

150. Chen, S.; Huang, L.; Li, G.; Qiu, F.; Wang, Y.; Yang, C.; Pan, J.; Wu, Z.; Chen, J.; Tian, Y. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglubin gene expression. *Clin. Epigenet.* 2020, 12, 168. [CrossRef] [PubMed]

151. Liu, C.; Wang, J.; Yuan, X.; Qian, W.; Zhang, B.; Shi, M.; Xie, J.; Shen, B.; Xu, H.; Hou, Z.; et al. Long noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression. *Oncotarget* 2016, 7, 71556–71566. [CrossRef]

152. Gao, Z.; Wang, Q.; Ji, M.; Guo, X.; Li, L.; Su, X. Exosomal IncRNA UCA1 modulates cervical cancer stem cell self-renewal and differentiation through microRNA-122-5p/SCX2 axis. *J. Transl. Med.* 2021, 19, 229. [CrossRef] [PubMed]